




UNED FIROLEG
GYMHWYSOL CYMRU

WAVU

WALES APPLIED
VIROLOGY UNIT



Ymchwil Iechyd
a Gofal Cymru
Health and Care
Research Wales



Ariennir gan
Lywodraeth Cymru
Funded by
Welsh Government

2025 - 2026 Annual report





Table of contents

Foreword	03
Introduction	04
Core metrics	06
The team	07
Meet our researchers	13
Case studies	19
Engagement	22
Looking forward	26

Foreword

Welcome to the end of the first year of the Wales Applied Virology Unit - or WAVU!

We were established in April 2025 with the aim of building on our existing strengths in viral research within Wales, increasing capacity to improve the lives of people living with viral disease, generate the next generation of therapeutics against viral infection, and establish viruses as platforms to control other diseases.

The team includes experts in discovery science, experimental medicine, clinical trials, population health, surveillance, and health psychology, with a core aim of bringing these disciplines together to accelerate our ability to make a change to patient lives.

Since getting started we have appointed our project officer, and have welcomed three new lecturers working across the broad disciplines that WAVU covers – one within our basic/translational focus, one on disease modelling, and a third on sexual health and behaviour. We have recently recruited a clinical research fellow who will begin in August 2026, and have established a staffed technology hub to bring in new technologies that will benefit researchers throughout Wales.

Finally, we have recruited a cohort of PhD students who will be starting in October 2026, to establish new projects and train up a group of researchers who are familiar with cross-disciplinary research.

We have also established our patient and public involvement and engagement (PPIE) panel, and have begun integrating them into the training of our staff and the projects they run.


In addition to getting ourselves established, we've completed a first-in-human trial of a viral therapeutic developed by a WAVU member, run a trial to reduce the chances of infection arising from female sanitary products in developing countries, built links with the UK Health Security Agency, been awarded prizes for our research, as well as capturing over £4.7m in grant funding, and publishing 33 scientific papers.

We're looking forward to what the next year brings!



Professor Richard Stanton
Co-Director, Wales Applied Virology Unit

Introduction





Introduction

Funded by Welsh Government via Health and Care Research Wales and based at Cardiff University, the Wales Applied Virology Unit (WAVU) is an interdisciplinary research unit focusing on virology.


Aims

To improve patient and public outcomes by integrating basic and translational virology with viral epidemiology and practice.

Mission statement

To improve the health of people living with viral disease **today** and reduce the burden of viral disease through the development and evaluation of intervention and control strategies.

To meet the needs of **tomorrow's** patients through the delivery of next generation advanced therapeutics, from enhanced vaccines to combat infectious disease and cancer, to engineered viral platforms for oncology and genome editing applications.



Core Metrics
Reporting period: 2025/2026

**Health and Care
Research Wales
infrastructure award
to the group**



Direct
funding
awarded
£600k

Jobs created
through direct
funding



Grants won during reporting period

Grants won	Led by group	Group collaborating
Number	15	4
Value	£4.1m	£4.8m
Funding to Wales	£4.1m	£2.4m
Funding to group	£3.5m	£1.2m
Additional jobs created for Wales	13	10
Additional jobs created for group	12	2



Number of publications




Number of public
engagement events



Number of public
involvement opportunities

The team



Centre structure 2025-2026

The current Centre leadership and delivery structure is as follows and receives advice and oversight from an External Advisory Board.

Co-Directors

Prof Richard Stanton

Prof Alan Parker

Dr David Gillespie

Lecturers

Dr Marieke Pinggen

Dr Adam Williams

Dr Rebecca Mancy

Tech Hub

Dr Rebecca Bayliss

Cameron Winch

Dr Gillian Seaton

Centre Manager

Zoe Evans

Centre structure 2025-2026

Co-Investigators

Prof Andrew Godkin

Dr Carly Bliss

Dr Ceri Fielding

Prof Ian Humphreys

Prof James White

Dr Honor Young

Partners

Dr Andrew Freedman

Dr Benjamin Gray

Dr Chris Williams

Patient and Public Involvement and Engagement

Steph Phillips

Mark Lewis

Jemin Popat



Co-Investigators

Hear from our co-investigators, outlining the research initiatives they are leading that align with and contribute to the objectives of the Wales Applied Virology Unit.

“We are interested in generating better vaccines to influenza A virus, and are testing different routes of vaccination with different vectors, incorporating modified, more immunogenic viral proteins. The overall aim is to generate superior protective immunity which will protect against different strains of influenza, including avian flu.”

Prof Andrew Godkin
Cardiff University



“Sexually transmitted infections (STIs) are currently at a 10-year high in England and Wales and are most prevalent among 15–24-year-olds. Over the last eight years, we have been working on the SaFE project, which provides on-site sexual health services and staff training on preventing dating and relationship violence in further education settings. We have now applied for funding for a full-scale evaluation of SaFE, which will involve 52 settings across England and Wales. Our hope is that, if effective, SaFE will promote sexual health, including reducing STIs, as well as reducing dating and relationship violence.”

Prof James White & Dr Honor Young
Cardiff University

Co-Investigators

“We develop therapies that harness the positive properties of viruses, specifically using them to train the immune system in the recognition and elimination of cells that have turned cancerous, or have been infected with a harmful viral pathogen. My research group ultimately aims to develop cancer therapeutics and infectious disease vaccines, and is exploring a number of ways to make such therapies more effective.”



Dr Carly Bliss
Cardiff University



“I am working on projects investigating interactions between viral proteins and immune cells, and how this could impact on the development of viral-induced disease. My work investigates how virus infection modulates immune cell function, and one of the main viruses I study is human cytomegalovirus (HCMV). HCMV causes serious disease in immunocompromised individuals, for example following transplantation, and is the major infectious cause of congenital birth defects.”

Dr Ceri Fielding
Cardiff University

“Our laboratory investigates the biological mechanisms that regulate immune responses to viruses, recognising that these responses can both protect against infection and drive harmful inflammation linked to diseases such as influenza, SARS-CoV-2, cytomegalovirus, and dementia. By defining how these immune pathways are controlled, we develop strategies to protect vulnerable individuals, reduce virus-induced inflammation in conditions including dementia and respiratory infections, and enhance the effectiveness of virus-based cancer vaccines.”



Prof Ian Humphreys
Cardiff University

Partners of WAVU

In this section, we hear directly from some of the partners of WAVU, who share insights into the projects and collaborations they are leading to advance virology research and public health impact across Wales.


"I am a clinical academic infectious disease physician and provide clinical input to WAVU. My current role involves conducting commercial clinical trials of new infection vaccines, including influenza and norovirus, in partnership with Health and Care Research Wales and the NIHR Vaccine Innovation Pathway."

Dr Andrew Freedman,
Consultant in Infectious Diseases at Cardiff University
and Cardiff & Vale UHB




"I lead a research programme in Public Health Wales spanning sexual health, substance use and health and justice. The research aligned to WAVU that I oversee includes generating population insights in to HIV knowledge, societal attitudes, and stigma. I am also interested in improving access to health care (for example, vaccine uptake) in some of our most marginalised communities across Wales."

Dr Benjamin Gray,
Communicable Disease Inclusion Health Programme,
Public Health Wales



Meet our researchers



Meet the researcher

Dr Marieke Pinggen

Lecturer in Infection and Immunity

As a lecturer in infection and immunity with a focus on viral encephalitis, Marieke joined WAVU in October 2025 and works as part of the basic virology workstream led by co-director, Professor Richard Stanton.



About me


I have always been interested in virology. During my PhD on transmission of HIV I worked closely with HIV clinicians and diagnostics, using laboratory methods to understand the mechanism and implications of problems observed in the patient population. For instance, using data generated for diagnostics we identified a cluster of people that contracted HIV with certain drug resistance mutations. We then tested these viruses in the laboratory against the latest HIV drugs, showing that they were highly effective against the patient virus strains. This directly improved treatment options for the people diagnosed with HIV containing these drug resistance mutations.

During my postdoc I focused on transmission of mosquito-transmitted viruses, as these are causing increasingly large and frequent outbreaks. We found that therapeutically improving the immune response at the bite site could improve disease outcome in mouse models.

A neuroimmunology professor who worked in the same building and I got talking about some of his PhD student's data, and my fascination with neuroscience was born. Many viruses, including HIV and mosquito-transmitted viruses, can cause viral encephalitis and it is very challenging to accurately diagnose which virus is causing the problems. Thus, there is an urgent need for better treatment strategies for viral encephalitis.

The research

My research is about how viral infection impacts the brain. Many viruses can reach our brain and cause inflammation, which causes substantial mortality and survivors often experience sequelae. It is very challenging to identify which pathogen is causing disease, and there are very few antiviral drugs available for treatment. I hope that by better understanding the immune response, we can eventually identify new treatment targets or strategies that can fight multiple viruses.



Human stem cell-derived mini brains (organoids) with brain immune cells (microglia) in red. The organoid on the right was infected with a green virus to study the brain's immune response.

Research impact

Thanks to the collaborative and interdisciplinary mission of WAVU, I have met many scientists and clinicians working within virology, immunology and neuroscience since moving to Cardiff. This allowed me to expand my research into using brain organoids, which are small 3D cultures made from human cells. These will be invaluable to understanding the differences and similarities between the antiviral immune responses generated against the most common pathogens causing viral encephalitis.

Meet the researcher

Dr Adam Williams

Lecturer in Infectious Disease Behavioural Science



A lecturer in infectious disease behavioural science and a co-applicant on the successful funding bid that established WAVU, Adam's work is driven by a commitment to improving sexual health through research, policy, and community engagement. Adam works as part of the viral epidemiology and practice workstream led by co-director, Dr David Gillespie.

About me

Coming from a socioeconomically deprived background, I have a strong personal and professional motivation to make health systems more equitable. Sexual health is an area where issues of access, stigma, and innovation intersect in complex ways, often leaving those most in need underserved. My research aims not only to generate evidence, but to ensure that it is translated into meaningful improvements in services and policy, delivering real benefits for communities.

Alongside my academic role, I contribute to the wider field through several leadership and advisory positions. I am an Editor at Sexually Transmitted Infections (BMJ), Chair of Fast Track Cardiff and Vale, and a member of the UK HIV Outcomes Group. These roles enable me to support the translation of research into practice, influence policy discussions, and engage with national and local stakeholders.

The research

My research focuses on how people engage with testing, prevention, and treatment for HIV and other sexually transmitted infections.



The central problem I aim to address is the persistent gap between advances in sexual health innovation and equitable access to these advances in practice. While new interventions such as vaccines, diagnostics, and prevention strategies continue to emerge, access remains uneven, shaped by stigma, service design, socioeconomic barriers, and a lack of meaningful community engagement.

Research impact

Addressing inequalities in sexual health is both a public health priority and a matter of social justice. Improving access to testing, prevention, and care has the potential to reduce transmission, improve quality of life, and tackle longstanding health disparities.

A central element of my work is its contribution to the generation of policy-relevant evidence. This includes supporting the case for continued investment in the Wales National Postal Testing Service for STIs, a groundbreaking national programme that provides free, accessible testing at scale.

The impact of this work lies in its translational focus, bridging the gap between research, policy, and practice. By embedding stakeholder engagement throughout the research process, the work supports the development of services and interventions that are more effective, equitable, and sustainable.

Meet the researcher

Dr Rebecca Mancy

Lecturer in Infectious Disease Epidemiology & Behavioural Science

As a lecturer in infectious disease epidemiology and behavioural science, Rebecca is a mathematical epidemiological modeller interested in epidemiological dynamics, working as part of the viral epidemiology and practice workstream led by co-director, Dr David Gillespie.



About me

I love developing bespoke modelling methods to understand the epidemiology of infectious diseases. I am particularly drawn to counterintuitive effects that can arise in epidemiological dynamics. For example, our work on symptom propagation shows that, in some situations, quarantining *only* severe cases can reduce the number of severe cases over the course of an epidemic, and in some situations, even the total number of cases.

I am also excited to learn from the interdisciplinary team that I have joined at WAVU. I'm interested in the mechanisms of disease transmission, how these affect the biology of infection, and how this, in turn, influences the dynamics of epidemics. I am therefore keen to learn more about the biology of infection, including the role of the body's immune response.

The research

My natural tendency is to be curious about a diverse range of ideas. I am currently interested in two main areas: the processes of disease transmission and how these affect epidemics, and in the long-term dynamics of infectious diseases and how these change over the epidemiological transition. With respect to the processes of disease transmission, I've been working recently with researchers at the University of Warwick and University of Liverpool on "symptom propagation", which occurs when an infected person's symptoms (like severity) influence the symptoms experienced by a person they infect. For example, the route of transmission or pathogen dose might influence the severity of symptoms.

Research impact

History provides many examples of 'natural experiments' and situations that we cannot – or do not want to – repeat today, and that can help us to answer fundamental questions about disease dynamics and provide insights into how to manage them. We recently analysed data from a large epidemic of cerebrospinal fever, today known as meningococcal meningitis, with a view to gaining insights into how we might manage outbreaks such as that seen recently in Kent. Our analysis showed that outbreaks of the scale of the one in Kent are far from unprecedented in the UK and confirmed the importance of overcrowding and close contact for transmission. They also highlighted the importance of spatially localised and targeted antibiotic delivery and vaccination to avoid recurrent cases in affected areas and suggested that there might be location-specific but unidentified risk factors that further study could potentially uncover, making outbreaks appear less random.

In earlier work, we used a 'natural experiment' from history to demonstrate the effect of prior local disease burden on vaccine refusal decisions, a finding which could help target vaccine messaging today.



Technological Hub

Our technology hub can design viruses, proteins, and organoids to support your research.



A hub for designing
advanced biological
systems that shape the
future of therapeutics
and research

Viruses

Led by Dr Rebecca Bayliss

As part of the Viral Immunotherapies and Advanced Therapeutics Laboratory (VITAL) lead by Prof Alan Parker at Cardiff University, my research revolves around the development of cancer targeting viruses that can directly deliver anti-cancer medicines to tumor cells reducing the toxicity of current treatments.

My role extends to the WAVU Technology Hub where I am able to provide technological support for virology based research including; virus production, testing of anti-viral products, design and generation of bespoke Adenovirus based vectors and viruses for applications such as gene therapy, vaccine development and cancer virotherapies.

Addressing key areas of research such as virus-host interactions, viral evolution, anti-viral and vaccine development and translational development of viruses through the use of new technologies, will shape the future of virology research to effectively combat the challenges presented by viruses and improve public health outcomes.

Proteins

Led by Cameron Winch

Our protein production and purification platforms provide expert support for research groups requiring high-quality recombinant proteins for a wide range of research applications. We're continually improving our technologies and can tailor workflows to the specific needs of each project.

We offer a multi-species production platform, encompassing three established expression systems: Mammalian, Insect and E.coli. This allows for production of proteins across a broad spectrum of complexity. We hold a diverse library of expression plasmids and vector systems, allowing flexible and rapid adaption to project needs

Scalable purification methodologies, including affinity and size exclusion chromatography, are available to deliver proteins at quantities suited to a wide range of applications. Currently, we are supporting the production of proteins including solubilised ligands and receptors for use in binding, functional, structural, and immunological studies. The service is also supporting the production of bispecific antibodies for therapeutic and mechanistic investigation.

Organoids

Led by Dr Gillian Seaton

I am a post doctoral molecular biologist with extensive experience in a wide range of research disciplines including Neuroscience and Oncology. My focus has been to tackle some of the most significant diseases with societal impact such as Dementia in our aging population, and Cancer in multiple organs such a breast, prostate and brain using patient derived xenograft models. This broad experience has enabled me to optimise the culture of various organ specific cell lines and patient derived material in 3D models.

I am excited to implement this expertise in delivering organoid models for the testing of potential therapeutics across the Wales Applied Virology Unit's remit.

In collaboration with Dr Anu Goenka, Senior Lecturer at Bristol Vaccine Centre and Honorary Consultant in Paediatric Immunology & Infectious Diseases at Bristol Royal Hospital for Children, we are establishing models of human adaptive immunity in the form of organoid tonsil culture. Human tonsil organoids preserve features such as antigen-specific antibody production, somatic hypermutation and affinity maturation, plasmablast differentiation and class-switch recombination. This can be used as a platform for testing vaccine candidates, assessing adjuvants in a human-relevant system, and exploring autoimmune mechanisms.

Dr Philip Savage, Clinical Academic in Cancer Immuno-oncology at Cardiff University, recently shared how utilising the services of the Tech Hub has assisted his research:

“

You can source standard viruses from many sources, but having one engineered precisely for your experimental protocol is something much more valuable. A bespoke, GMO-compliant construct built to your specifications is invaluable to improve your research and secure onward funding.

”



Case studies


Our case studies highlight how research partnerships and evidence-based innovation are driving meaningful impact across communities, sectors, and disciplines. Each example showcases real-world applications of our work, demonstrating how rigorous research translates into practical solutions and measurable benefits.

Dr Emily Bates


Developing "smart viruses" (precision virotherapies) for treating glioblastoma, building on her success as a Brain Tumour Charity Future Leaders Fellow

*Glioblastoma is the most common aggressive brain cancer with poor survival rates. There is limited success with current treatments, like **immunotherapies** that use the body's own immune cells to fight off cancer. This is because the surrounding area of the tumour stops the immune system from doing its job – this is known as a '**cold**' tumour environment.*

*The VITAL group adapts Ad5, a type of adenovirus, into a '**smart virus**' that can find, infect and kill cancer cells in the body. **Adenoviruses** are commonly used to make vaccines, gene therapies and oncolytic (cancer-killing) technologies.*



*Our goal is to turn our smart viruses into new treatments for glioblastoma with fewer off-target effects. We have developed a smart virus, called **Ad5 RGD**, that can target a marker on glioblastoma cells but not on surrounding healthy cells. Dr Emily Bates is generating newer versions of our smart viruses that deliver a blueprint to make immunotherapies directly within tumour cells. These smart viruses re-ignite the immune system, turning a '**cold**' tumour environment into a '**hot**' environment primed for **cancer killing**. We are exploring ways we can further improve these smart viruses, like using switches to turn the immunotherapy on, but only in the cancer cells. We are aiming to move this new treatment into **clinical trials**, like our other smart virus, to offer hope for people living with glioblastoma.*



Dr Adam Williams

Positive Futures: HIV, Ageing, Futures and Care: A study exploring the housing and social care needs of people ageing with HIV in Wales

The Positive Futures project is an exploratory study focused on understanding the housing, social care, and ageing needs of people living with HIV aged 50 and over in Wales. The project adopts a multi-stage, mixed-methods design, including a scoping review, qualitative interviews, prioritisation activities, and a final consensus process to identify key issues and future research priorities. The study is currently in its set-up phase, with the scoping review underway. This initial stage is systematically mapping existing evidence to identify key concepts, gaps, and areas requiring further investigation, providing a critical foundation to inform subsequent data collection and stakeholder engagement activities.

A distinctive and innovative element of Positive Futures is its strong commitment to participatory research, particularly through the involvement of trained co-researchers with lived experience of HIV. These co-researchers will play an active role in shaping the study design, co-facilitating interviews, and contributing to data analysis, ensuring that the research is grounded in real-world perspectives and experiences. This approach enhances the relevance, credibility, and inclusivity of the findings, while also supporting meaningful community engagement throughout the research process. By embedding co-production at its core, the project is well positioned to generate actionable insights that are both academically robust and directly applicable to policy and service development.




Hannah Preston

Engineering antibodies to outsmart a stealth virus: Developing next-generation immunotherapies against Human Cytomegalovirus (HCMV)

Viruses are masters of disguise - one of the most skilled is HCMV. Although usually harmless in healthy individuals, HCMV can cause severe, sometimes life-threatening disease in newborn babies, transplant recipients, and people with weakened immune systems. Despite decades of research, there is still no licensed vaccine, and current antivirals are limited by toxicity, resistance, and an inability to eliminate lifelong infection.

Previous attempts to block the virus from entering cells have shown limited success. HCMV persists by hiding within host cells and employing sophisticated evasion strategies to avoid detection by the immune system. Our research focuses on targeting these hiding places directly.


We investigated how antibodies can recruit natural killer (NK) cells - the immune system's specialised "assassins" - to recognise and kill infected cells through a process called antibody-dependent cellular cytotoxicity (ADCC).



We successfully developed novel engineered antibodies designed to better activate NK cells and overcome viral immune evasion. These therapies showed strong antiviral activity, reducing virus spread and improving targeted killing of infected cells, while outperforming conventional therapies at very low doses with no detectable toxicities.

This work demonstrates a promising new strategy for controlling HCMV and may help support the development of next-generation immunotherapies against other difficult-to-treat viral infections.

Engagement



Patient and Public Involvement and Engagement

Patient and public involvement and engagement (PPIE) is essential to the success of WAVU. By involving those most affected by infectious diseases in shaping priorities, guiding study design, and interpreting findings, the centre ensures its work remains grounded in real-world needs and experiences.

Our aim is for our PPIE work to strengthen the relevance, transparency, and impact of our research across the full spectrum; from fundamental laboratory science to implementation in communities and healthcare settings. This ultimately enables discoveries to translate more effectively into meaningful improvements in public health.



Profile of WAVU PPIE investigators

Stephanie Phillips

Steph is a Chief People Officer and mum to two children living with a rare genetic disorder. She is a PPIE member for the OCTO MILI Clinical Trial SteerCo; a trustee for The George Pantziarka TP53 Trust; a PPIE advocate for Oxford Cancer and the Wales Paediatric Cancer Predisposition Group.

“

Why involve patient and public leads? Because there is no one more driven, no one with more purpose, than someone living with the condition you are looking to cure. Understanding our stories creates awareness but also it creates purpose, it provides a human connection to the research and it demonstrates that what can be achieved, day in and day out, matters.

”

Mark Lewis

Mark is a Senior Policy Officer for the All-Party Parliamentary Group on HIV/AIDs and Sexual Health. He was previously also a volunteer for Fast Track Cardiff & Vale and a Trustee for Positively UK.

“

Nothing about us without us isn't just a slogan—it's a safeguard. PPIE ensures the people who live with a condition, navigate the system, or carry the burden of care have a real seat at the table, not a token chair. Because research and services designed for people, but without them, miss the mark every time.

”

Public involvement plans for WAVU

In addition to integrating PPIE within individual projects, our PPIE investigators are invited to our interdisciplinary group meetings to share their experiences and contribute to discussions about the ongoing and upcoming work associated with WAVU. As WAVU PhD students are enrolled, we also plan to develop bespoke PPIE training, particularly acknowledging the added complexity of effectively involving and engaging lay representatives in laboratory-based research.



Events and Activities

WAVU has been fortunate to be invited to participate in a number of public engagement activities throughout this year, providing valuable opportunities to raise the profile of the Unit and strengthen our connections with the wider community.

Our stall had a 'build-a-virus' activity designed to explain the concept of how we can engineer viruses to be used to treat disease such as cancer, and virus themed temporary tattoos - which were very popular!



Looking forward

The first year of the Wales Applied Virology Unit has been firmly focused on building strong foundations. During this time, we have assembled an exciting and dynamic interdisciplinary team and established ourselves as a cohesive and ambitious Unit. As we move forward, we look forward to adding the final pieces to the jigsaw through the recently recruited clinical research fellow who will begin in August 2026, and the recruitment of our inaugural PhD cohort, who will begin their studies in earnest this October.


Our technology hub has become a central driver of activity, generating bespoke viruses, proteins, and organoids that are enabling and enhancing research across Cardiff, Wales, and the wider UK. At the same time, our newly recruited lecturers have hit the ground running. Supported by dedicated start-up funding and the expertise within the technology hub, they are already producing promising early data and demonstrating the value of our collaborative, interdisciplinary approach.

A key priority for the Unit moving forward will be ensuring that patient and public involvement and engagement (PPIE) is embedded throughout our research activities. We are committed to building meaningful partnerships with patients, communities, and public contributors to help shape research priorities, improve communication and engagement, and ensure our work delivers tangible benefits to society. By integrating PPIE into project development, training, and dissemination activities, we aim to foster research that is both scientifically excellent and socially relevant.

Looking ahead to 2026-2027, our focus shifts from establishing foundations to building momentum. Continued investment in our new principal investigators remains a priority, particularly through the provision of WAVU-funded PhD studentships. We are excited to nurture this new generation of scientists, providing them with the environment, mentorship, and resources needed to thrive. By supporting these researchers to generate high quality data and develop innovative research programmes, we aim to create the platform for future funding success and sustained growth in virology capacity.

Together, these developments position the Wales Applied Virology Unit to become a leading centre for virology research, innovation, training, and public engagement, with impact across Wales, the UK, and internationally.





Contact us

For more information about collaborating with our research team
or to keep up to date with news and events:




cardiff.ac.uk/wales-applied-virology-unit



WAVU@cardiff.ac.uk



linkedin.com/company/wales-applied-virology-unit



**Scan here to join
our newsletter**

